Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA002637 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA002637, RRID:AB_1846432
- Product name
- Anti-CDK6
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human CDK6, Gene description: cyclin-dependent kinase 6, Alternative Gene Names: PLSTIRE, Validated applications: WB, IHC, ICC, Uniprot ID: Q00534, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Proliferation of hippocampal progenitors relies on p27-dependent regulation of Cdk6 kinase activity.
Li Q, Jiang B, Guo J, Shao H, Del Priore I, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian A, Rees M, Ronan M, Roth J, Donovan K, Palafox M, Reis-Filho J, de Stanchina E, Fischer E, Rosen N, Serra V, Koff A, Chodera J, Gray N, Chandarlapaty S
Cancer Discovery 2022;12(2):356-371
Cancer Discovery 2022;12(2):356-371
Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis
Redl E, Sheibani-Tezerji R, Cardona C, Hamminger P, Timelthaler G, Hassler M, Zrimšek M, Lagger S, Dillinger T, Hofbauer L, Draganić K, Tiefenbacher A, Kothmayer M, Dietz C, Ramsahoye B, Kenner L, Bock C, Seiser C, Ellmeier W, Schweikert G, Egger G
Life Science Alliance 2020;4(2):e202000794
Life Science Alliance 2020;4(2):e202000794
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis
Müller A, Dickmanns A, Resch C, Schäkel K, Hailfinger S, Dobbelstein M, Schulze-Osthoff K, Kramer D
Journal of Clinical Investigation 2020;130(11):5765-5781
Journal of Clinical Investigation 2020;130(11):5765-5781
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown D, Da Cruz Paula A, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho J, Chandarlapaty S
Cancer Cell 2018;34(6):893-905.e8
Cancer Cell 2018;34(6):893-905.e8
Proliferation of hippocampal progenitors relies on p27-dependent regulation of Cdk6 kinase activity.
Caron N, Genin EC, Marlier Q, Verteneuil S, Beukelaers P, Morel L, Hu MG, Hinds PW, Nguyen L, Vandenbosch R, Malgrange B
Cellular and molecular life sciences : CMLS 2018 Oct;75(20):3817-3827
Cellular and molecular life sciences : CMLS 2018 Oct;75(20):3817-3827
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in Rh30 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-CDK6 antibody. Remaining relative intensity is presented. Loading control: Anti-PPIB.
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human placenta and skeletal muscle tissues using HPA002637 antibody. Corresponding CDK6 RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
